Sharesource Remote Patient Management Platform Shows Promising Results in Reducing Home Dialysis Technique Failure
DEERFIELD, Ill. - In a breakthrough announcement, Baxter International Inc. (NYSE:BAX) has unveiled new data suggesting that its Sharesource remote patient management (RPM) digital platform, used in conjunction with an automated peritoneal dialysis (PD) system, is associated with a remarkable 77% reduction in the risk of PD technique failure. This groundbreaking development offers hope and improved outcomes for patients undergoing home dialysis.
Technique failure in peritoneal dialysis can occur due to various factors, resulting in patients needing to switch to in-center dialysis. However, this recent research conducted during the annual Kidney Week has shown that the implementation of Baxter’s Sharesource platform significantly lowers the risk of technique failure. This puts Baxter at the forefront of transforming the landscape of kidney care and vital organ support.
Peritoneal dialysis is a crucial treatment option for patients with end-stage renal disease (ESRD), offering greater flexibility and improved quality of life compared to in-center hemodialysis. Traditionally, patients on peritoneal dialysis face the challenge of managing their treatment independently. However, with the integration of Baxter’s Sharesource remote patient management platform, healthcare providers and patients can now effectively monitor and address any potential issues in real-time.
Sharesource allows healthcare professionals to remotely access and analyze patient data collected from the automated peritoneal dialysis system. This enhances communication and collaboration between healthcare providers and patients, leading to timely interventions and improved outcomes. By leveraging the power of technology, Baxter aims to revolutionize the way kidney care is delivered and improve patient satisfaction and clinical outcomes.
The recent data revealing a remarkable 77% reduction in the risk of PD technique failure holds significant promise. Patients undergoing peritoneal dialysis can now be reassured that access to advanced remote monitoring tools will provide them with enhanced support, minimizing the likelihood of complications and reducing the need for transition to in-center dialysis.
In addition to the groundbreaking research findings, Baxter International Inc’s suppliers have recorded an impressive 25.36% increase in sales year on year in Q3 2023. This growth is a testament to the company’s commitment to innovation and collaboration throughout its supply chain. Furthermore, despite facing challenges, Baxter International Inc has demonstrated resilience, with only a minor deterioration of -1.86% in its cost of sales year on year. In comparison to the previous quarter, the cost of sales fell by a negligible -0.19% in Q3.
The combination of Baxter’s technological advancements, showcased through the Sharesource remote patient management platform, and the company’s strong performance in sales highlights its dedication to transforming kidney care. With these innovative solutions, patients can look forward to improved outcomes, enhanced quality of life, and a more streamlined approach to managing their condition.
In conclusion, Baxter International Inc’s Sharesource platform has demonstrated significant potential in revolutionizing peritoneal dialysis outcomes and reducing the risk of technique failure. The integration of remote patient monitoring tools enables effective collaboration between patients and healthcare providers, ensuring timely interventions and improved clinical outcomes. Moreover, the positive sales growth and resilience showcased by Baxter International Inc further reinforce the company’s commitment to pushing the boundaries of kidney care. Through innovative solutions and transformative technologies, Baxter continues to pave the way for better patient experiences and improved treatment outcomes.
Comments